We are live on ! Find out more
ABI

Adamant Biomedical Investments Portfolio holdings

AUM $418M
This Fund
S&P 500
This Quarter Est. Return
+5.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
–
Cap. Flow
+$398M
Cap. Flow %
99.27%
Top 10 Hldgs %
34.69%
Holding
96
New
96
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.2M
2
CELG
Celgene Corp
CELG
+$18.7M
3
BIIB icon
Biogen
BIIB
+$18.1M
4
CYTO
Altamira Therapeutics Ltd
CYTO
+$13.4M
5
AMGN icon
Amgen
AMGN
+$13.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 86.61%
2 Financials 1.21%
3 Industrials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
76
DELISTED
Medicines Co
MDCO
$1.12M 0.28%
+50,000
New +$1.27M
LDRH
77
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
$1.03M 0.26%
+33,000
New +$855K
MYGN icon
78
Myriad Genetics
MYGN
$311M
$926K 0.23%
+24,000
New +$895K
NPSP
79
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$884K 0.22%
+34,000
New +$977K
ACAD icon
80
Acadia Pharmaceuticals
ACAD
$5.06B
$867K 0.22%
+35,000
New +$819K
ACHN
81
DELISTED
Achillion Pharmaceuticals
ACHN
$798K 0.2%
+80,000
New +$743K
AFFX
82
DELISTED
Affymetrix Inc
AFFX
$798K 0.2%
+100,000
New +$857K
COR icon
83
Cencora
COR
$62B
$773K 0.19%
+10,000
New +$760K
NBIX icon
84
Neurocrine Biosciences
NBIX
$16.8B
$705K 0.18%
+45,000
New +$673K
IMMU
85
DELISTED
Immunomedics Inc
IMMU
$558K 0.14%
+150,000
New +$507K
HALO icon
86
Halozyme
HALO
$12.2B
$546K 0.14%
+60,000
New +$571K
WCG
87
DELISTED
Wellcare Health Plans, Inc.
WCG
$483K 0.12%
+8,000
New +$530K
IPXL
88
DELISTED
Impax Laboratories, Inc.
IPXL
$474K 0.12%
+20,000
New +$512K
EXEL icon
89
Exelixis
EXEL
$13.1B
$459K 0.11%
+300,000
New +$963K
CLDX icon
90
Celldex Therapeutics
CLDX
$3.37B
$389K 0.1%
+2,000
New +$436K
VIVS
91
VivoSim Labs
VIVS
$1.27M
$319K 0.08%
+208
New +$377K
TBPH icon
92
Theravance Biopharma
TBPH
$876M
$263K 0.07%
+11,428
New +$332K
INFI
93
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$228K 0.06%
+17,000
New +$202K
GERN icon
94
Geron
GERN
$949M
$90K 0.02%
+45,000
New +$111K
DNDN
95
DELISTED
DENDREON CORPORATION
DNDN
$72K 0.02%
+50,000
New +$87.6K
1 2 3
4

Similar funds

AGCJ
Alden Global Capital (Jersey) St. Helier, Jersey $415M AUM 31.95% 1-Year Est. Return
ACM
Alistair Capital Management Dallas, Texas $391M AUM 5.89% 1-Year Est. Return
RNS
Robert N. Shapiro $501M AUM 11.7% 1-Year Est. Return
NTP
Nine Ten Partners Evanston, Illinois $308M AUM
MMC
MDV Management Company Menlo Park, California $296M AUM
LOM
Loeb Offshore Management New York $547M AUM 50.11% 1-Year Est. Return
CAMI
Concord Asset Management (Illinois) Chicago, Illinois $288M AUM 11.06% 1-Year Est. Return
NES
New England Securities New York $285M AUM 7.18% 1-Year Est. Return

Adamant Biomedical Investments's Q3 2014 Portfolio in Review

Q3 2014 is the first quarter with a 13F filing on record for Adamant Biomedical Investments, which disclosed 96 positions worth $401M. Its ten largest holdings account for 35% of the portfolio.

Its largest position is Gilead Sciences: 196,390 shares worth $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, followed by Financials and Industrials.

  • Adamant Biomedical Investments's largest Q3 2014 buy was Gilead Sciences: 196,390 shares worth $20.9M.
  • Adamant Biomedical Investments's ten largest holdings make up 35% of its $401M portfolio in Q3 2014.
  • Adamant Biomedical Investments disclosed 96 positions in Q3 2014, its first 13F filing on record.

Based on Adamant Biomedical Investments's 13F filing for Q3 2014, filed 14 Nov 2014.